There are numerous genes involved in the DDR pathway, and several studies suggest that platinum therapy may benefit patients with mutations in genes such as ATM and ATR, those within the MRN complex (e.g., RAD50), and Fanconi anemia core genes. This evidence concerns the gene RAD50 and Fanconi anemia.